This clinical trial is studying extensive stage small cell lung cancer, a fast-growing type of lung cancer that has already spread widely in the body. The study is testing Lutathera (lutetium (177Lu) oxodotreotide) given together with carboplatin, etoposide, and atezolizumab during the first part of treatment, and then with atezolizumab alone during the later treatment phase. The purpose of the study is to find the best dose of Lutathera and to see whether adding it may help people live longer. In the first part of the study, people receive the treatment combination and the dose is adjusted to find a suitable amount. In the second part, one group receives Lutathera with the standard treatment, while another group receives the standard treatment without Lutathera. Treatment is given over several visits, with follow-up after treatment to see how the disease and treatment effects change over time.
Some people in the study may also receive NETSPOT (dotatate) for a special body scan, and LysaKare (arginine hydrochloride, lysine hydrochloride) may be given to help protect the kidneys during treatment with Lutathera. The study also includes checks for side effects and general safety, and treatment may be stopped or changed if the medicine is not tolerated. This trial is focused on newly diagnosed extensive stage small cell lung cancer and uses a combination of cancer medicine, immune treatment, and a targeted radioactive medicine.
Austria 
Belgium 
Czechia 
France 
Germany 
Italy 
Spain 
The Netherlands 
